Ocular Therapeutix, Inc. Announces Pricing of Public Offering of Common Stock
January 24 2017 - 8:00AM
Business Wire
Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced today the
pricing of a registered underwritten public offering of 3,571,429
shares of its common stock at a public offering price of $7.00 per
share pursuant to a shelf registration statement that was
previously filed with and declared effective by the Securities and
Exchange Commission (SEC). All of the shares in the offering are to
be sold by the Company.
Cantor Fitzgerald & Co. is acting as the sole bookrunner for
the offering.
The offering is expected to close on or about January 27, 2017,
subject to customary closing conditions.
Before investing in the offering, interested parties may read
the prospectus supplement and the accompanying prospectus for the
offering and the other documents the Company has filed with the
SEC, which are incorporated by reference in the prospectus
supplement and the accompanying prospectus for the offering and
provide more complete information about the Company and the
offering. An electronic copy of the prospectus supplement and the
accompanying prospectus for the offering will be available on the
website of the SEC at www.sec.gov. Copies of the final prospectus
supplement, when available, and the accompanying prospectus
relating to this offering may be obtained by contacting Cantor
Fitzgerald & Co., Attn: Capital Markets, 499 Park Ave., 5th
Floor, New York, New York 10022, or by telephone at 212-829-7122,
or by e-mail at prospectus@cantor.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities, in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful, prior to registration or
qualification under the securities laws of any such state or
jurisdiction. Offers will be made only by means of a prospectus
supplement and the accompanying prospectus, forming a part of the
registration statement.
About Ocular TherapeutixOcular Therapeutix, Inc. is a
biopharmaceutical company focused on the development and
commercialization of innovative therapies for diseases and
conditions of the eye using its proprietary hydrogel platform
technology. Ocular Therapeutix has resubmitted a new drug
application (NDA) for post-surgical pain for its lead product
candidate, DEXTENZA, which has completed Phase 3 clinical
development for post-surgical ocular inflammation and pain. Subject
to the approval of the NDA for post-surgical ocular pain, Ocular
Therapeutix intends to submit a supplemental NDA for DEXTENZA to
broaden its label to include an indication for post-surgical
inflammation. DEXTENZA is also in Phase 3 clinical development for
allergic conjunctivitis. OTX-TP is in Phase 3 clinical development
for glaucoma and ocular hypertension. Ocular Therapeutix is also
evaluating injectable drug delivery depots for back-of-the-eye
diseases. Ocular Therapeutix's first product, ReSure® Sealant, is
FDA-approved to seal corneal incisions following cataract
surgery.
Forward Looking StatementsAny statements in this press
release about future expectations, plans and prospects for the
Company including the development and regulatory status of the
Company’s product candidates, such as the Company’s expectations
and plans regarding regulatory submissions for and the timing and
conduct of clinical trials of DEXTENZA for the treatment of
post-surgical ocular inflammation and pain, including the Company’s
expectations regarding the NDA filed with the FDA and the
resubmission of the NDA, DEXTENZA for the treatment of allergic
conjunctivitis and OTX-TP for the treatment of glaucoma and ocular
hypertension, the ongoing development of the Company’s injectable
drug delivery depots for back-of-the-eye diseases, the potential
utility of any of the Company’s product candidates, the potential
commercialization of the Company’s product candidates, the
Company’s expectations related to the offering discussed in this
press release and other statements containing the words
"anticipate," "believe," "estimate," "expect," "intend," "goal,"
"may," "might," "plan," "predict," "project," "target,"
"potential," "will," "would," "could," "should," "continue," and
similar expressions, constitute forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors. Such forward-looking statements involve substantial risks
and uncertainties that could cause the Company’s clinical
development programs, future results, performance or achievements
to differ significantly from those expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, those related to the timing and costs involved in
commercializing ReSure® Sealant or any product candidate that
receives regulatory approval, the initiation and conduct of
clinical trials, availability of data from clinical trials and
expectations for regulatory submissions and approvals, the
Company’s scientific approach and general development progress, the
availability or commercial potential of the Company’s product
candidates, the sufficiency of cash resources and need for
additional financing or other actions and other factors discussed
in the “Risk Factors” section contained in the Company’s current
quarterly and annual reports on file with the Securities and
Exchange Commission. In addition, the forward-looking statements
included in this press release represent the Company’s views as of
the date of this release. The Company anticipates that subsequent
events and developments will cause the Company’s views to change.
However, while the Company may elect to update these
forward-looking statements at some point in the future, the Company
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing the Company’s views as of any date subsequent to the
date of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170124005780/en/
InvestorsOcular Therapeutix, Inc.Brad SmithChief
Financial Officerbsmith@ocutx.comorBurns McClellan on behalf of
Ocular TherapeutixSteve Klass,
212-213-0006sklass@burnsmc.comorMediaMedical DynamicsCynthia
Sutherland, 646-599-8635Media Group
Directorcsutherland@rxmedyn.comorOcular Therapeutix, Inc.Scott
CorningVice President of Marketing & Commercial
Operationsscorning@ocutx.com
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Apr 2023 to Apr 2024